Jennifer Mak Sells 75 Shares of Axon Enterprise (NASDAQ:AXON) Stock

Key Points

• Jennifer Mak, Chief Accounting Officer of Axon Enterprise, sold 75 shares at an average price of $723.50, reducing her ownership by 0.49% to a total of 15,080 shares valued at approximately $10.91 million.
• Axon Enterprise reported a quarterly earnings per share of **$2.12**, significantly surpassing expectations of **$1.54**, with revenues of **$668.54 million**, reflecting a **32.6%** year-over-year increase.
• Following recent transactions, **79.08%** of Axon Enterprise's stock is currently owned by institutional investors, highlighting strong interest from large stakeholders.

Axon Enterprise, Inc (NASDAQ:AXON - Get Free Report) CAO Jennifer Mak sold 75 shares of the stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $723.50, for a total value of $54,262.50. Following the transaction, the chief accounting officer owned 15,080 shares of the company's stock, valued at approximately $10,910,380. This represents a 0.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Axon Enterprise Trading Down 2.5%

Axon Enterprise stock traded down $18.30 during midday trading on Wednesday, reaching $725.29. 635,030 shares of the stock traded hands, compared to its average volume of 696,405. The company has a 50-day simple moving average of $770.41 and a two-hundred day simple moving average of $678.20. Axon Enterprise, Inc has a 12-month low of $346.71 and a 12-month high of $885.91. The firm has a market cap of $56.94 billion, a PE ratio of 179.08, a price-to-earnings-growth ratio of 27.43 and a beta of 1.40. The company has a current ratio of 2.95, a quick ratio of 2.71 and a debt-to-equity ratio of 0.63.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The biotechnology company reported $2.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.58. The business had revenue of $668.54 million during the quarter, compared to analysts' expectations of $641.77 million. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The business's quarterly revenue was up 32.6% compared to the same quarter last year. During the same quarter last year, the business posted $1.20 EPS. Axon Enterprise has set its FY 2025 guidance at EPS. Research analysts expect that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. Wolfe Research started coverage on Axon Enterprise in a research report on Monday, July 7th. They issued an "outperform" rating on the stock. Northland Securities set a $800.00 target price on Axon Enterprise in a research note on Tuesday, August 5th. Barclays increased their target price on Axon Enterprise from $726.00 to $735.00 and gave the stock an "overweight" rating in a research report on Friday, May 9th. JPMorgan Chase & Co. lifted their target price on Axon Enterprise from $730.00 to $850.00 and gave the stock an "overweight" rating in a report on Thursday, July 17th. Finally, Craig Hallum upgraded Axon Enterprise from a "hold" rating to a "buy" rating and set a $900.00 price target for the company in a research report on Tuesday, August 5th. Thirteen investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $837.69.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Vanguard Group Inc. raised its stake in shares of Axon Enterprise by 3.5% in the second quarter. Vanguard Group Inc. now owns 8,937,260 shares of the biotechnology company's stock valued at $7,399,515,000 after purchasing an additional 305,252 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Axon Enterprise by 5.9% in the second quarter. Geode Capital Management LLC now owns 2,072,186 shares of the biotechnology company's stock valued at $1,713,332,000 after purchasing an additional 115,349 shares in the last quarter. Alliancebernstein L.P. raised its stake in shares of Axon Enterprise by 15.9% in the first quarter. Alliancebernstein L.P. now owns 1,284,935 shares of the biotechnology company's stock valued at $675,812,000 after purchasing an additional 175,890 shares in the last quarter. Westfield Capital Management Co. LP raised its stake in shares of Axon Enterprise by 29.8% in the first quarter. Westfield Capital Management Co. LP now owns 927,801 shares of the biotechnology company's stock valued at $487,977,000 after purchasing an additional 212,931 shares in the last quarter. Finally, Vestor Capital LLC raised its stake in shares of Axon Enterprise by 438,636.3% in the second quarter. Vestor Capital LLC now owns 833,599 shares of the biotechnology company's stock valued at $690,170,000 after purchasing an additional 833,409 shares in the last quarter. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.